227 related articles for article (PubMed ID: 15482201)
1. Fluconazole for the treatment of candidiasis: 15 years experience.
Cha R; Sobel JD
Expert Rev Anti Infect Ther; 2004 Jun; 2(3):357-66. PubMed ID: 15482201
[TBL] [Abstract][Full Text] [Related]
2. Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia.
Rodríguez-Tudela JL; Almirante B; Rodríguez-Pardo D; Laguna F; Donnelly JP; Mouton JW; Pahissa A; Cuenca-Estrella M
Antimicrob Agents Chemother; 2007 Oct; 51(10):3599-604. PubMed ID: 17646421
[TBL] [Abstract][Full Text] [Related]
3. [INVESTIGATION ON ANTIFUNGAL SUSCEPTIBILITY OF CANDIDA YEASTS IN PREGNANT PATIENTS WITH CONFIRMED VULVOVAGINAL CANDIDIASIS AND THEIR NEWBORNS.].
Chokoeva A; Kouzmanov A; Ivanova Z; Zisova L; Amalie G; Petleshkova P; Miteva-Katrandzhieva T; Krasteva M; Uchikova E
Akush Ginekol (Sofiia); 2016; 55(4):20-29. PubMed ID: 29370489
[TBL] [Abstract][Full Text] [Related]
4. Fluconazole for the management of invasive candidiasis: where do we stand after 15 years?
Charlier C; Hart E; Lefort A; Ribaud P; Dromer F; Denning DW; Lortholary O
J Antimicrob Chemother; 2006 Mar; 57(3):384-410. PubMed ID: 16449304
[TBL] [Abstract][Full Text] [Related]
5. [Fluconazole. A new antimycotic for systemic use].
Hartzen SH; Frimodt-Møller N; Korner B
Ugeskr Laeger; 1990 Aug; 152(32):2321-4. PubMed ID: 2205037
[No Abstract] [Full Text] [Related]
6. Vulvovaginal candidiasis in a Flemish patient population.
De Vos MM; Cuenca-Estrella M; Boekhout T; Theelen B; Matthijs N; Bauters T; Nailis H; Dhont MA; Rodriguez-Tudela JL; Nelis HJ
Clin Microbiol Infect; 2005 Dec; 11(12):1005-11. PubMed ID: 16307555
[TBL] [Abstract][Full Text] [Related]
7. Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis.
Petraitis V; Petraitiene R; Groll AH; Sein T; Schaufele RL; Lyman CA; Francesconi A; Bacher J; Piscitelli SC; Walsh TJ
Antimicrob Agents Chemother; 2001 Feb; 45(2):471-9. PubMed ID: 11158743
[TBL] [Abstract][Full Text] [Related]
8. Fluconazole: optimized antifungal therapy based on pharmacokinetics.
Silling G
Mycoses; 2002; 45 Suppl 3():39-41. PubMed ID: 12690970
[TBL] [Abstract][Full Text] [Related]
9.
Lu H; Shrivastava M; Whiteway M; Jiang Y
Crit Rev Microbiol; 2021 May; 47(3):323-337. PubMed ID: 33587857
[TBL] [Abstract][Full Text] [Related]
10. [A new pharmaceutical concept for the therapy of oropharyngeal and esophageal candidiasis with fluconazole].
Wildfeuer A; Laufen H; Yeates RA; Zimmermann T
Mycoses; 1996; 39 Suppl 1():123-6. PubMed ID: 8767284
[TBL] [Abstract][Full Text] [Related]
11. The fluconazole era: management of hematogenously disseminated candidiasis in the nonneutropenic patient.
Kramer KM; Skaar DJ; Ackerman BH
Pharmacotherapy; 1997; 17(3):538-48. PubMed ID: 9165556
[TBL] [Abstract][Full Text] [Related]
12. The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women.
Sobel JD; Ohmit SE; Schuman P; Klein RS; Mayer K; Duerr A; Vazquez JA; Rampalo A;
J Infect Dis; 2001 Jan; 183(2):286-93. PubMed ID: 11204125
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic evaluation of fluconazole in critically ill patients.
Sinnollareddy M; Peake SL; Roberts MS; Playford EG; Lipman J; Roberts JA
Expert Opin Drug Metab Toxicol; 2011 Nov; 7(11):1431-40. PubMed ID: 21883033
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis.
Hata K; Kimura J; Miki H; Toyosawa T; Moriyama M; Katsu K
Antimicrob Agents Chemother; 1996 Oct; 40(10):2243-7. PubMed ID: 8891122
[TBL] [Abstract][Full Text] [Related]
15. Fluconazole: a new option in the treatment of Candida mucositis and esophageal candidiasis.
Garber GE
J Otolaryngol; 1992 Apr; 21(2):92-4. PubMed ID: 1583715
[TBL] [Abstract][Full Text] [Related]
16. [Diagnosis, treatment and prevention of infections caused by fungi in HIV-positive patients].
Fortun Abete J
Rev Clin Esp; 1995 Oct; 195 Suppl 3():4-14. PubMed ID: 9441305
[No Abstract] [Full Text] [Related]
17. Efficacy and safety of a single oral 150 mg dose of fluconazole for the treatment of vulvovaginal candidiasis in Japan.
Mikamo H; Matsumizu M; Nakazuru Y; Okayama A; Nagashima M
J Infect Chemother; 2015 Jul; 21(7):520-6. PubMed ID: 25887336
[TBL] [Abstract][Full Text] [Related]
18. [The statement of Polish Gynecological Society Experts on the etiology and treatment of recurrent vulvovaginal candidiasis].
Ginekol Pol; 2011 Nov; 82(11):869-73. PubMed ID: 22384623
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Recurrent Vulvovaginal Candidiasis With Ibrexafungerp.
Grant LM; Orenstein R
J Investig Med High Impact Case Rep; 2022; 10():23247096221123144. PubMed ID: 36059275
[TBL] [Abstract][Full Text] [Related]
20. Biofilms Formed by Isolates from Recurrent Vulvovaginal Candidiasis Patients Are Heterogeneous and Insensitive to Fluconazole.
Sherry L; Kean R; McKloud E; O'Donnell LE; Metcalfe R; Jones BL; Ramage G
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
